New Study: Non-Viral Substance Can Be Antiviral by Boosting the Immune System

Share Article

The Center for the Biology of Chronic Disease points out that the synthetic protein EP67 was shown to be antiviral by stimulating the immune system against the flu virus in a new study published by the journal PLoS ONE.

A vaccine boosts the immune system against a certain virus by injecting the weakened or dead virus. Until now, vaccines were the only tool doctors routinely used in preventing diseases caused by viruses. Things are changing. A new tool is emerging. According to a new animal study reviewed by the Center for the Biology of Chronic Disease (CBCD) the synthetic protein EP67 was antiviral by stimulating the immune system against the flu virus.

The effect of EP67 on the tested animals was phenomenal. "Mice normally lose about 20 percent of their body weight when exposed to the flu, but the mice treated with the protein lost an average of only 6 percent. Some didn't lose any weight at all." (ABC Report) Moreover, mice infected with a lethal dose of influenza did not die after receiving the protein. The study was conducted by researchers from San Diego State University and the University Of Nebraska Medical Center.

The importance of this study is in showing that a substance, other than the virus itself, can be antiviral, not by directly killing the virus, but by boosting the immune system.

It is interesting that this study is maybe the first to follow the plan laid out by the CBCD almost 10 years ago. Since the publication of the Purple book by Dr. Hanan Polansky in 2003, the CBCD has been advocating the revolutionary concept of antiviral treatments by boosting the immune system with non-viral substances.

According to Dr. Hanan Polansky's theory of Microcompetition, as put forward in his highly acclaimed Purple book entitled "Microcompetition with Foreign DNA and the Origin of Chronic Disease," latent viruses, while still latent, cause most major diseases. In contrast, many scientists believe today that latent viruses can only cause disease if reactivated. Reactivation means that the virus begins to produce all of its proteins and make copies of itself on a large scale.

Why is Dr. Polansky's discovery important?

Most people harbor a latent virus. However, they have no symptoms caused by reactivation. These people and their doctors assume that since they have no reactivation symptoms they are safe. These doctors are wrong. The latently infected people are at risk of developing a major disease even if they don’t have the usual viral symptoms.

Scientists know that latent viruses replicate on a small scale even when they are not reactivated, that is, they don't cause the usual symptoms. As stated by Dr. Hanan Polansky, each latent virus is in a constant state of microcompetition with human genes for limited genetic resources, and as a result, can drive the human genes to malfunction, and cause disease.

As anyone can see, a latent virus is not harmless. It isn’t dead, and since it continues to express some of its proteins and microcompete with the human genes, it can cause disease.
Consider the paper entitled “Human Cytomegalovirus Persistence” published February 13, 2012 in the journal, Cellular Microbiology. [1]

“Both the chronic and latent states of infection contribute to HCMV persistence and to the high HCMV seroprevalence worldwide. The chronic infection is poorly defined molecularly, but clinically manifests as low-level virus shedding over extended periods of time and often in the absence of symptoms.”

A virus is still shedding copies of itself during the latent phase, meaning it still replicates, and still causes microcompetition with human genes.

The same paper goes on to say: “Transcripts and proteins encoded from a region encompassing the major immediate early region are detected in hematopoietic cells following infection in vitro as well as in latently infected individuals.” (Kondo et al., 1996; Landini et al., 2000).

What does it all mean?

As said before, latent viruses continue to replicate, and therefore can cause disease even without reactivation, that is, without showing the usual symptoms.

Listen to Dr. Polansky describing his discovery during a recent interview by clicking on the following link.

"The key to your health is to reduce the level of latent viruses in your body to harmless levels." – Dr. Hanan Polansky

So how does one reduce latent viruses?

It’s not easy. There are two traditional ways to attack the latent EBV virus: through vaccines and through antiviral medications. Currently there are no vaccines or drugs on the market to combat the latent viruses. The CBCD is encouraged however, by immune boosting results of the animal study using EP67, and looks forward to more research being conducted on this synthetic protein.
In the meantime, the CBCD would like to point out a natural product currently on the market designed to target latent viruses. The name of that natural product is Gene-Eden-VIR.

For more information on the Center for the Biology of Chronic Disease, or to schedule an interview with one of our researchers, please visit or call 585-250-9999.


[1] Goodrum F, Caviness K, Zagallo P. “Human Cytomegalovirus Persistence”, Cellular Microbiology, May 14, 2012


The Center for the Biology of Chronic Disease (CBCD, is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.

We invite biologists, virologists, scientists everywhere to download Dr. Polansky’s book, “Microcompetition with Foreign DNA and the Origin of Chronic Disease” here:
The CBCD published the “Purple” book by Dr. Hanan Polansky..

The book presents Dr. Polansky’s highly acclaimed scientific theory on the relationship between the DNA of latent (chronic) viruses and the onset of chronic diseases. Dr. Polansky’s book is available as a free download from the CBCD website.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John S. Boyd, PhD
(585) 250-9999
Email >
Visit website